# Charlie's Holdings, Inc.: financial statements, quarterly

CHUC · OTC · CIK 1134765 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/chuc.md) · [Financials](/companies/chuc/financials.md) · [Filings](/companies/chuc/filings.md) · [Insiders](/companies/chuc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/chuc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,706](/filings/0001437749-24-035717.md) | [5,544 d](/filings/0001437749-24-012061.md) | [3,051](/filings/0001437749-25-021440.md) | [2,043](/filings/0001437749-25-027482.md) | [1,624](/filings/0001437749-25-035731.md) | [1,047 d](/filings/0001437749-26-010761.md) | [1,578](/filings/0001437749-26-017948.md) | [1,761](/filings/0001437749-26-028182.md) | [7,084](/filings/0001437749-25-035731.md) | [8,982 d](/filings/0001437749-26-010761.md) | [4,804](/filings/0001437749-26-017948.md) | [3,802](/filings/0001437749-26-028182.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | [994](/filings/0001437749-25-035731.md) | [522 d](/filings/0001437749-26-010761.md) | [1,192](/filings/0001437749-26-017948.md) | [1,275](/filings/0001437749-26-028182.md) | [5,322](/filings/0001437749-25-035731.md) | [6,281 d](/filings/0001437749-26-010761.md) | [3,624](/filings/0001437749-26-017948.md) | [2,684](/filings/0001437749-26-028182.md) |
| Gross profit | $k | not reported | not reported | not reported | not reported | [630](/filings/0001437749-25-035731.md) | [525 d](/filings/0001437749-26-010761.md) | [386](/filings/0001437749-26-017948.md) | [486](/filings/0001437749-26-028182.md) | [1,762](/filings/0001437749-25-035731.md) | [2,701 d](/filings/0001437749-26-010761.md) | [1,180](/filings/0001437749-26-017948.md) | [1,118](/filings/0001437749-26-028182.md) |
| Research and development | $k | [41.0](/filings/0001437749-23-031976.md) | [37.0 d](/filings/0001437749-24-012061.md) | [6.0](/filings/0001437749-24-017669.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(742)](/filings/0001437749-24-035717.md) | [99.0 d](/filings/0001437749-25-018798.md) | [(941)](/filings/0001437749-25-021440.md) | [(736)](/filings/0001437749-25-027482.md) | [(876)](/filings/0001437749-25-035731.md) | [(751) d](/filings/0001437749-26-010761.md) | [(879)](/filings/0001437749-26-017948.md) | [(954)](/filings/0001437749-26-028182.md) | [(339)](/filings/0001437749-25-035731.md) | [(123) d](/filings/0001437749-26-010761.md) | [(975)](/filings/0001437749-26-017948.md) | [(1,234)](/filings/0001437749-26-028182.md) |
| Interest expense | $k | [121](/filings/0001437749-23-031976.md) | [114 d](/filings/0001437749-24-012061.md) | [183](/filings/0001437749-24-017669.md) | [156](/filings/0001437749-25-027482.md) | [146](/filings/0001437749-25-035731.md) | [218 d](/filings/0001437749-26-010761.md) | [241](/filings/0001437749-26-017948.md) | [333](/filings/0001437749-26-028182.md) | [37.0](/filings/0001437749-25-035731.md) | [78.0 d](/filings/0001437749-26-010761.md) | [75.0](/filings/0001437749-26-017948.md) | [81.0](/filings/0001437749-26-028182.md) |
| Income tax | $k | [0.0](/filings/0001437749-23-031976.md) | [0.0 d](/filings/0001437749-25-018798.md) | not reported | [0.0](/filings/0001437749-25-027482.md) | [0.0](/filings/0001437749-25-035731.md) | [0.0 d](/filings/0001437749-26-010761.md) | [0.0](/filings/0001437749-26-017948.md) | [388](/filings/0001437749-26-028182.md) | [0.0](/filings/0001437749-25-035731.md) | [(151) d](/filings/0001437749-26-010761.md) | [0.0](/filings/0001437749-26-017948.md) | [0.0](/filings/0001437749-26-028182.md) |
| Net income | $k | [(708)](/filings/0001437749-24-035717.md) | [(27.0) d](/filings/0001437749-25-018798.md) | [(1,045)](/filings/0001437749-25-021440.md) | [(967)](/filings/0001437749-25-027482.md) | [(1,022)](/filings/0001437749-25-035731.md) | [(1,125) d](/filings/0001437749-26-010761.md) | [(1,217)](/filings/0001437749-26-017948.md) | [4,961](/filings/0001437749-26-028182.md) | [624](/filings/0001437749-25-035731.md) | [131 d](/filings/0001437749-26-010761.md) | [(1,050)](/filings/0001437749-26-017948.md) | [(1,662)](/filings/0001437749-26-028182.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001437749-24-035717.md) | not reported | [0.00](/filings/0001437749-25-021440.md) | [0.00](/filings/0001437749-25-035731.md) | [0.00](/filings/0001437749-25-035731.md) | not reported | [0.00](/filings/0001437749-25-021440.md) | [0.00](/filings/0001437749-25-035731.md) | [0.00](/filings/0001437749-25-035731.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [0.00](/filings/0001437749-24-035717.md) | not reported | [0.00](/filings/0001437749-25-021440.md) | [0.00](/filings/0001437749-25-035731.md) | [0.00](/filings/0001437749-25-035731.md) | not reported | [(0.01)](/filings/0001437749-26-017948.md) | [0.02](/filings/0001437749-26-028182.md) | [0.00](/filings/0001437749-25-035731.md) | not reported | [0.00](/filings/0001437749-26-017948.md) | [(0.01)](/filings/0001437749-26-028182.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.7](/filings/0001437749-23-031976.md) | [0.4](/filings/0001437749-25-018798.md) | [0.2](/filings/0001437749-24-017669.md) | [1.1](/filings/0001437749-24-027186.md) | [0.6](/filings/0001437749-24-035717.md) | [0.2](/filings/0001437749-26-010761.md) | [0.1](/filings/0001437749-25-021440.md) | [1.5](/filings/0001437749-25-027482.md) | [1.2](/filings/0001437749-25-035731.md) | [1.3](/filings/0001437749-26-028182.md) | [0.6](/filings/0001437749-26-017948.md) | [0.5](/filings/0001437749-26-028182.md) |
| Current assets | $m | [5.8](/filings/0001437749-23-031976.md) | [5.1](/filings/0001437749-25-018798.md) | [4.2](/filings/0001437749-24-017669.md) | [4.8](/filings/0001437749-24-027186.md) | [3.9](/filings/0001437749-24-035717.md) | [3.7](/filings/0001437749-26-010761.md) | [3.0](/filings/0001437749-25-021440.md) | [5.8](/filings/0001437749-25-027482.md) | [9.8](/filings/0001437749-25-035731.md) | [10.8](/filings/0001437749-26-028182.md) | [14.1](/filings/0001437749-26-017948.md) | [12.0](/filings/0001437749-26-028182.md) |
| Total assets | $m | [6.6](/filings/0001437749-23-031976.md) | [5.8](/filings/0001437749-25-018798.md) | [4.7](/filings/0001437749-24-017669.md) | [5.2](/filings/0001437749-24-027186.md) | [4.2](/filings/0001437749-24-035717.md) | [3.9](/filings/0001437749-26-010761.md) | [3.2](/filings/0001437749-25-021440.md) | [6.0](/filings/0001437749-25-027482.md) | [10.6](/filings/0001437749-25-035731.md) | [11.6](/filings/0001437749-26-028182.md) | [14.8](/filings/0001437749-26-017948.md) | [12.8](/filings/0001437749-26-028182.md) |
| Current liabilities | $m | [5.7](/filings/0001437749-23-031976.md) | [4.8](/filings/0001437749-25-018798.md) | [5.6](/filings/0001437749-24-017669.md) | [5.4](/filings/0001437749-24-027186.md) | [5.3](/filings/0001437749-24-035717.md) | [5.6](/filings/0001437749-26-010761.md) | [5.8](/filings/0001437749-25-021440.md) | [3.6](/filings/0001437749-25-027482.md) | [6.8](/filings/0001437749-25-035731.md) | [7.6](/filings/0001437749-26-028182.md) | [9.3](/filings/0001437749-26-017948.md) | [7.2](/filings/0001437749-26-028182.md) |
| Total liabilities | $m | [6.9](/filings/0001437749-23-031976.md) | [5.9](/filings/0001437749-25-018798.md) | [5.8](/filings/0001437749-24-017669.md) | [5.5](/filings/0001437749-24-027186.md) | [5.5](/filings/0001437749-24-035717.md) | [5.7](/filings/0001437749-26-010761.md) | [6.0](/filings/0001437749-25-021440.md) | [3.8](/filings/0001437749-25-027482.md) | [7.3](/filings/0001437749-25-035731.md) | [8.1](/filings/0001437749-26-028182.md) | [11.7](/filings/0001437749-26-017948.md) | [9.7](/filings/0001437749-26-028182.md) |
| Long-term debt | $m | [2.8](/filings/0001437749-23-031976.md) | [2.5](/filings/0001437749-24-012061.md) | [2.8](/filings/0001437749-24-017669.md) | [2.0](/filings/0001437749-24-027186.md) | [2.6](/filings/0001437749-24-035717.md) | [2.2](/filings/0001437749-25-018798.md) | [3.1](/filings/0001437749-25-021440.md) | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(0.2)](/filings/0001437749-24-035717.md) | [(0.1)](/filings/0001437749-26-010761.md) | [(1.1)](/filings/0001437749-25-027482.md) | [(0.3)](/filings/0001437749-25-035731.md) | [(1.3)](/filings/0001437749-25-035731.md) | [(1.8)](/filings/0001437749-26-028182.md) | [(2.8)](/filings/0001437749-26-028182.md) | [2.2](/filings/0001437749-26-028182.md) | [3.2](/filings/0001437749-25-035731.md) | [3.4](/filings/0001437749-26-028182.md) | [3.1](/filings/0001437749-26-028182.md) | [3.1](/filings/0001437749-26-028182.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(860) d](/filings/0001437749-24-035717.md) | [(47.0) d](/filings/0001437749-25-018798.md) | [(431)](/filings/0001437749-25-021440.md) | [131 d](/filings/0001437749-25-027482.md) | [(944) d](/filings/0001437749-25-035731.md) | [(377) d](/filings/0001437749-26-010761.md) | [(409)](/filings/0001437749-26-017948.md) | [(2,654) d](/filings/0001437749-26-028182.md) | [(3,109) d](/filings/0001437749-25-035731.md) | [394 d](/filings/0001437749-26-010761.md) | [(1,105)](/filings/0001437749-26-017948.md) | [(383) d](/filings/0001437749-26-028182.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-23-031976.md) | [0.0 d](/filings/0001437749-24-012061.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [244](/filings/0001437749-23-031976.md) | [212](/filings/0001437749-24-017669.md) | [245](/filings/0001437749-24-027186.md) | [217](/filings/0001437749-24-035717.md) | [221](/filings/0001437749-25-021440.md) | [243](/filings/0001437749-25-035731.md) | [243](/filings/0001437749-25-035731.md) | [254](/filings/0001437749-26-017948.md) | [282](/filings/0001437749-26-028182.md) | [278](/filings/0001437749-25-035731.md) | [268](/filings/0001437749-26-017948.md) | [274](/filings/0001437749-26-028182.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 280,553,242 at 2026-08-17, from the cover of the [10-Q filed 2026-08-17](/filings/0001437749-26-028182.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.